Product Details
- Genetically modified cell lines best reflect MOA (Mechanism of Action)
- Higher activity and larger assay window for robust and reproducible cell-based bioassay
- Comprehensive application data to support assay development and validation
- Full tracible record, stringent quality control and validated cell passage stability
- Parental cell line legally obtained from internationally recognized cell resource bank and commercially licensed
- Global commercial license assistance whenever regulatory filing is required
Description
The HEK293/Human GCGR Stable Cell Line was engineered to express the receptor full length human GCGR (Uniprot: P47871), with different levels of GCGR expression (High, Medium, Low). Surface expression of human GCGR was confirmed by flow cytometry.
Application
• Useful for cell-based GCGR binding assay
• Screen for human GCGR agonists based on cAMP accumulation assay
Growth Properties
Adherent
Selection Marker
Hygromycin B (20 μg/mL)
Complete Growth Medium
DMEM + 10% FBS
Freeze Medium
Serum-free cell cryopreservation medium
Quantity
1 vial contains at least 5×10^6 cells in 1 mL serum-free cryopreservation medium
Storage
Frozen in liquid nitrogen.
Mycoplasma Testing
Negative
Sterility Testing
Negative
Instructions for Use
See data sheet for detailed culturing and assay protocol.
ACRO Quality Management System
Customers Also Viewed
Performance Data
Receptor Assay

Expression analysis of human GCGR on HEK293/Human GCGR Stable Cell Line by FACS.
Cell surface staining using Alexa 488-labeled anti-human GCGR antibody was performed on HEK293/Human GCGR Stable Cell Line with different expression levels: HEK293/Human GCGR Stable Cell Line (Low Expression); HEK293/Human GCGR Stable Cell Line (Medium Expression); HEK293/Human GCGR Stable Cell Line (High Expression).Protocol
Application

cAMP accumulation assay for human GCGR agonist screening.
HEK293/Human GCGR Stable Cell
Line (Low Expression), HEK293/Human GCGR Stable Cell Line (Medium Expression) and HEK293/Human
GCGR Stable Cell Line (High Expression) were stimulated with Retatrutide TFA, respectively. The EC50 of
Retatrutide TFA on HEK293/Human GCGR Stable Cell Line (Medium Expression) was approximately 0.000241
μM.Protocol
Customer Reviews Writing Reviews

Important Statement
Limited Use&License Disclosure
BY USE OF THIS PRODUCT, RESEARCHER AGREES TO BE BOUND BY THE FOLLOWING TERMS OF LIMITED USE OF THIS CELL LINE PRODUCT.
- If the researcher is not willing to accept the terms of limited use of this cell line product, and the product is unused, ACRO will accept return of the unused product.
- Researchers may use this product for research use only, no commercial use is allowed. "Commercial use" means any and all uses of this product and derivatives by a party for profit or other consideration and may include but is not limited to use in: (1) product manufacture; and (2) to provide a service, information or data; and/or resale of the product or its derivatives, whether or not such product or derivatives are resold for use in research.
- This cell line is neither intended for any animal or human therapeutic purposes nor for any direct human in vivo use. You have no right to share, modify, transfer, distribute, sell, sublicense, or otherwise make the cell line available for use to other researchers, laboratories, research institutions, hospitals, universities, or service organizations.
- ACROBIOSYSTEMS MAKES NO WARRANTIES OR REPRESENTATIONS OF ANY KIND, EITHER EXPRESSED OR IMPLIED, WITH RESPECT TO THE SUITABILITY OF THE CELL LINE FOR ANY PARTICULAR USE.
- ACROBIOSYSTEMS ACCEPTS NO LIABILITY IN CONNECTION WITH THE HANDLING OR USE OF THE CELL LINE.
- Modifications of the cell line, transfer to a third party, or commercial use of the cell line may require a separate license and additional fees. Please contact order@acrobiosystems.com for further details.
Recent Advances
- English Name:
Glucagon receptor
- Category:
- Approved Drugs:
6 Details
- Drugs in Clinical Trials:
40 Details
- Highest Development Stage:
Approved
전화
글로벌: +1 800-810-0816 (무료)
아시아태평양: +86 400-682-2521



















